Bevor Sie zu YouTube weitergehen

Alphabet, Google’s parent, announced an $84.75 billion equity offering to fund artificial intelligence investments. The company said it plans to spend $180 billion to $190 billion on AI this year, citing progress from Gemini across products and cloud, plus a deal with Apple to power next-gen models. Investors face potential dilution, though the raise is about 2% of its $4.3 trillion market cap.

Cipher Digital Inc. (NASDAQ:CIFR) rose for a second day, up 8.26% to close at $24.50, tracking a broader market rally tied to easing US-Iran tensions, according to the article. Earlier this week, it raised $800 million via 5-year senior secured notes yielding 6%. Proceeds fund its Stingray data center (15-year AWS lease) and related costs, with notes guaranteed by Cipher Stingray.

Duke Energy said the U.S. Department of Energy selected it for a grant of up to $61.8 million to refurbish and improve reliability of coal-fired plants in Kentucky and North Carolina. The company will negotiate final amounts for East Bend Station (up to $33.4 million) and Roxboro units 2 and 3 (up to $28.4 million). Duke said DOE funding for its projects totals nearly $96 million.

Bath & Body Works’ shares have struggled in 2026 as investors weigh slowing sales growth and category pressures, according to the article. In Q1, the company reported net sales of $1.4 billion, down 3% year over year, and said consumer uncertainty and a challenging retail environment persisted. Body care declined in the mid-teens, Retail Dive reported. CEO Daniel Heaf said its multi-year transformation is on track.

Ascent Industries (NASDAQ:ACNT) said it is intentionally shifting revenue from custom manufacturing toward product sales, which it expects to be more predictable and margin accretive. Product sales rose from ~10% of sales in 2023 to ~27% in 2024 and ~30% last year. Management cited $7M and $10M net-new business from recent customer wins, underutilized assets (~45% utilization), and a $14M Midwest Graphic Sales acquisition (closed early May) with $10.8M revenue and ~$2M adjusted EBITDA.

Arcadia Biosciences (Nasdaq: RKDA) said it closed a $4 million private placement under Nasdaq rules, selling 3,883,496 shares of common stock (or pre-funded warrants) plus Series A-1 and A-2 preferred investment options to buy up to 3,883,496 shares each at $1.03/share. Gross proceeds were about $4 million. H.C. Wainwright & Co. was placement agent; proceeds will fund working capital and general corporate purposes.